Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension

Julien Bissonnette, Juan Carlos Garcia‐Pagán, Agustín Albillos, Fanny Turon, Carlos Ferreira, Luis Tellez, Jean‐Charles Nault, Nicolas Carbonell, Jean‐Paul Cervoni, Mohamed Abdel Rehim, Annie Sibert, Louis Bouchard, Pierre Perreault, Jonel Trebicka, Félix Trottier‐Tellier, Pierre‐Emmanuel Rautou, Dominique‐Charles Valla, Aurélie Plessier – 17 March 2016 – Idiopathic noncirrhotic portal hypertension is a heterogeneous group of diseases characterized by portal hypertension in the absence of cirrhosis.

Soluble Adenylyl Cyclase Regulates Bile Salt‐Induced Apoptosis in Human Cholangiocytes

Jung‐Chin Chang, Simei Go, Dirk R. de Waart, Patricia Munoz‐Garrido, Ulrich Beuers, Coen C. Paulusma, Ronald Oude Elferink – 17 March 2016 – Anion exchanger 2 (AE2), the principal bicarbonate secretor in the human biliary tree, is down‐regulated in primary biliary cholangitis. AE2 creates a “bicarbonate umbrella” that protects cholangiocytes from the proapoptotic effects of bile salts by maintaining them deprotonated. We observed that knockdown of AE2 sensitized immortalized H69 human cholangiocytes to not only bile salt‐induced apoptosis (BSIA) but also etoposide‐induced apoptosis.

Lorcaserin Use in the Management of Morbid Obesity in a Pre‐Liver Transplant Patient

Julio A. Gutierrez, Carmen Landaverde, Jennifer T. Wells, Fred Poordad – 17 March 2016 – Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m2. Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited.

Lorcaserin Use in the Management of Morbid Obesity in a Pre‐Liver Transplant Patient

Julio A. Gutierrez, Carmen Landaverde, Jennifer T. Wells, Fred Poordad – 17 March 2016 – Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m2. Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited.

Suppression of lethal‐7b and miR‐125a/b Maturation by Lin28b Enables Maintenance of Stem Cell Properties in Hepatoblasts

Yasuo Takashima, Maiko Terada, Miyako Udono, Shizuka Miura, Junpei Yamamoto, Atsushi Suzuki – 17 March 2016 – In liver development, hepatoblasts that act as hepatic stem/progenitor cells proliferate and differentiate into both hepatocytes and cholangiocytes to form liver tissues. Although numerous factors contribute to this event, little is known about the roles of microRNAs in hepatoblast proliferation and differentiation.

Development and Validation of a Disease‐Specific Questionnaire to Assess Patient‐Reported Symptoms in Polycystic Liver Disease

Myrte K. Neijenhuis, Tom J.G. Gevers, Marie C. Hogan, Patrick S. Kamath, Titus F.M. Wijnands, Ralf C.P.M. van den Ouweland, Marie E. Edwards, Jeff A. Sloan, Wietske Kievit, Joost P.H. Drenth – 11 March 2016 – Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD‐related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease‐specific questionnaire that assesses symptoms in PLD (PLD‐Q).

Subscribe to